Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 5mg 5mg Capsule 68,908,116 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE BGR G Losartan potassium - 100mg, Hydrochlorothiazide - 25mg Tablet, coated 439,436 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 5mg 5mg Capsule, hard 71,647,217 L.L
C09DA01 LOSANET-H FORTE G Losartan potassium - 100mg, Hydrochlorothiazide - 12.5mg Tablet 395,474 L.L
L04AX04 LEDOBOOK 10 G Lenalidomide - 10mg 10mg Capsule 62,230,245 L.L
A02BC01 LOZICARE G Omeprazole - 40mg 40mg Injectable powder for solution 12,446,972 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard 14,449,637 L.L
L04AX04 LIDAMID 10 G Lenalidomide - 10mg 10mg Capsule 75,120,146 L.L
L04AX04 LENALIDOMIDE OHRE PHARMA G Lenalidomide - 10mg 10mg Capsule 30,336,491 L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 10mg 10mg Capsule 72,248,183 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 10mg 10mg Capsule, hard 75,120,146 L.L
L04AX04 LEDOBOOK 15 G Lenalidomide - 15mg 15mg Capsule 62,230,245 L.L
N03AX09 LAMOTRIGINE NORMON G Lamotrigine - 100mg 100mg Tablet, dispersible/ chewable 2,284,532 L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard 15,241,884 L.L
N03AX09 LAMOTRIGINE ARROW LAB G Lamotrigine - 100mg 100mg Tablet, dispersible/ chewable 1,050,885 L.L
A08AB01 LESSFAT G Orlistat - 120mg 120mg Capsule 391,634 L.L
L04AX04 LIDAMID 15 G Lenalidomide - 15mg 15mg Capsule 79,238,426 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 100mg 100mg Tablet, dispersible 1,233,647 L.L
A08AB01 LESSFAT G Orlistat - 60mg 60mg Capsule 1,039,238 L.L
L04AX04 LENALIDOMIDE OHRE PHARMA G Lenalidomide - 15mg 15mg Capsule 30,336,491 L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 15mg 15mg Capsule 76,209,421 L.L
N03AX09 LEPIGINE G Lamotrigine - 100mg 100mg Tablet, scored 1,163,768 L.L
C10BA05 LIPONORM PLUS 10/10 G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet 1,975,448 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard 15,343,847 L.L
N03AX09 LAMOTRIGINE ARROW LAB G Lamotrigine - 25mg 25mg Tablet, dispersible/ chewable 556,351 L.L
C10BA05 LIPONORM PLUS 20/10 G Atorvastatin - 20mg, Ezetimibe - 10mg Tablet 2,680,966 L.L
H02AB04 LISAMETHYLE G Methylprednisolone sodium succinate - 40mg/2ml 40mg/2ml Injectable powder for solution+diluent 7,905,545 L.L
L04AX04 LIDAMID 25 G Lenalidomide - 25mg 25mg Capsule 87,161,381 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 25mg 25mg Tablet, dispersible 595,322 L.L
L04AX04 LENALIDOMIDE OHRE PHARMA G Lenalidomide - 25mg 25mg Capsule 30,336,491 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025